FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Antaria API Deviations Cited

FDA warns Australias Antaria Pty. Ltd. about CGMP deviations in its production of active pharmaceutical ingredients.

latest-news-card-1
Human Drugs

Vanda Case Could Produce Legislation: Report

A Congressional Research Service paper points to possible legislation Congress may want to consider to clarify how FDA is to use confidential informat...

latest-news-card-1
Medical Devices

10 FDA Advisors Had Financial Ties with Abbott: KFF

A KFF Health News report carried online by NBC says 10 members of an FDA advisory committee evaluating an Abbott cardiac device had received money fro...

latest-news-card-1
Marketing

Methodological Rigor Info May Help Promotions: OPDP

CDER Office of Prescription Drug Promotion researchers say disclosing methodological rigor in communications to healthcare providers may help them for...

latest-news-card-1
Human Drugs

Alkem Labs Hit With 10-item Form-483

An FDA inspection last month at Alkem Laboratories India manufacturing facility leads to a 10-observation Form FDA-483.

latest-news-card-1
Medical Devices

Philips Respironics Consent Decree Approved

A federal court approves an FDA-brokered consent decree against Philips Respironics over its defective breathing devices.

latest-news-card-1
Human Drugs

ViiV Wins Adolescent HIV Use for Dovato

FDA approves ViiV Healthcares Dovato (dolutegravir/lamivudine) for treating HIV-1 infection in adolescents with no antiretroviral treatment history or...

latest-news-card-1
Human Drugs

Stealth Bio NDA for Barth Syndrome Accepted

FDA accepts for review a Stealth BioTherapeutics NDA for elamipretide for treating Barth syndrome.

latest-news-card-1
Human Drugs

Spirair Nasal Septal Deviation Device Cleared

FDA clears a Spirair 510(k) for its SeptAlign system for treating nasal septal deviation.

latest-news-card-1
Human Drugs

Carvykti Approved for Expanded Myeloma Use

FDA approves a supplemental BLA submitted by Janssen for Carvykti (ciltacabtagene autoleucel) to treat adults with relapsed or refractory myeloma who ...